Tandem Diabetes Care (NASDAQ:TNDM) Coverage Initiated by Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of Tandem Diabetes Care (NASDAQ:TNDM) in a research note published on Tuesday, MarketBeat Ratings reports. The firm issued a hold rating and a $15.00 price target on the medical device company’s stock.

Other analysts have also recently issued research reports about the stock. UBS Group reduced their price objective on shares of Tandem Diabetes Care from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, August 7th. Royal Bank Of Canada reduced their price objective on shares of Tandem Diabetes Care from $45.00 to $25.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tandem Diabetes Care in a research note on Wednesday, October 8th. Finally, Oppenheimer initiated coverage on shares of Tandem Diabetes Care in a research note on Monday, September 8th. They issued an “outperform” rating and a $22.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $21.19.

Tandem Diabetes Care Stock Down 1.0%

Shares of Tandem Diabetes Care stock opened at $15.39 on Tuesday. The company has a market cap of $1.04 billion, a P/E ratio of -4.98 and a beta of 1.48. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.88 and a current ratio of 2.44. Tandem Diabetes Care has a one year low of $9.98 and a one year high of $38.28. The firm has a fifty day moving average of $12.82 and a two-hundred day moving average of $16.40.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Wednesday, August 6th. The medical device company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.08). Tandem Diabetes Care had a negative return on equity of 65.40% and a negative net margin of 20.51%.The firm had revenue of $240.68 million for the quarter, compared to analysts’ expectations of $238.39 million. During the same quarter in the previous year, the company posted ($0.47) EPS. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. On average, analysts forecast that Tandem Diabetes Care will post -1.68 earnings per share for the current year.

Insider Activity

In other Tandem Diabetes Care news, CFO Leigh Vosseller bought 13,720 shares of the company’s stock in a transaction on Friday, August 8th. The stock was purchased at an average cost of $10.89 per share, for a total transaction of $149,410.80. Following the acquisition, the chief financial officer owned 25,580 shares of the company’s stock, valued at $278,566.20. The trade was a 115.68% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO John F. Sheridan bought 10,000 shares of the company’s stock in a transaction on Monday, August 11th. The shares were acquired at an average price of $10.23 per share, with a total value of $102,300.00. Following the completion of the acquisition, the chief executive officer directly owned 106,327 shares in the company, valued at $1,087,725.21. This represents a 10.38% increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of hedge funds and other institutional investors have recently modified their holdings of TNDM. Sessa Capital IM L.P. purchased a new stake in shares of Tandem Diabetes Care during the first quarter worth about $85,574,000. Ophir Asset Management Pty Ltd purchased a new stake in shares of Tandem Diabetes Care during the second quarter worth about $27,307,000. GW&K Investment Management LLC grew its holdings in shares of Tandem Diabetes Care by 34.9% during the first quarter. GW&K Investment Management LLC now owns 2,863,987 shares of the medical device company’s stock worth $54,874,000 after buying an additional 740,499 shares in the last quarter. Paradice Investment Management LLC grew its holdings in shares of Tandem Diabetes Care by 24.3% during the third quarter. Paradice Investment Management LLC now owns 2,196,468 shares of the medical device company’s stock worth $26,665,000 after buying an additional 429,289 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Tandem Diabetes Care during the first quarter worth about $5,907,000.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.